Review of antibody-based strategies against RSV and SARS-CoV-2 in infants
New antibody treatments for babies lower virus hospitalization risk greatly
This narrative review examines antibody-based strategies against respiratory syncytial virus and SARS-CoV-2 in infants. It reports that nirs…
A review of antibody treatments for babies shows they greatly lower hospitalization risk from respiratory viruses. These medicines stay effe…
Narrative review on pediatric RSV co-infections and post-pandemic rebound
RSV Hits Kids Harder When Another Bug Joins In
This narrative review synthesizes evidence on pediatric RSV co-infections in a global context.
It started with a sniffle. Then a cough. By day three, 7-month-old Mia was breathing fast, ribs pulling in with each breath.
ACIP Recommends Nirsevimab for Severe RSV Prevention in Infants and Young Children
Should more infants get protection against severe RSV?
The Advisory Committee on Immunization Practices (ACIP) has issued a recommendation for using nirsevimab to prevent severe respiratory syncy…
A national health committee now recommends a preventive shot called nirsevimab to help infants avoid severe breathing problems caused by the…
Field report describes nirsevimab rollout for RSV prevention in New York City infants
How many New York City infants got the new RSV shot this season?
A field report describes the rollout of nirsevimab for RSV prevention in infants born during the recommended administration period in New Yo…
New York City health officials released an early look at how many eligible infants received the new RSV shot this season.
RSV Immunization Coverage Among US Infants Receiving Nirsevimab or Maternal Vaccination
How many infants are getting new RSV protection? A first look
An observational report describes RSV immunization coverage among US infants born from October 2023 to March 2024 who received nirsevimab mo…
For the first time, doctors have tools to protect youngest babies from RSV with new shots or pregnancy vaccines.
Palivizumab reduces medically attended RSV infections in preterm infants, shows similar efficacy to nirsevimab
Can an older RSV drug protect healthy preterm babies from doctor visits?
A meta-analysis of three randomized, placebo-controlled studies in 2,464 healthy infants born ≤35 weeks' gestational age found palivizumab r…
An older RSV shot cuts doctor visits for preterm babies by 70%, matching newer drugs, though safety details remain unclear.